We developed an alternative in vitro ELISA to determine the E antigen content of the Japanese encephalitis virus to observe the 3Rs strategy.
Our study demonstrated that an in vitro assay could perform faster and was more convenient than the established in vivo PRNTest for JEV vaccine.
Thus, we propose a progressive switch from the in vivo assay to the in vitro ELISA for JEV vaccine quality control.